Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)
Latest Information Update: 16 Jun 2022
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Jun 2022 Status changed from active, no longer recruiting to completed.
- 26 May 2017 Planned End Date changed from 1 Jun 2020 to 19 Jun 2020.
- 05 Oct 2016 New trial record